>
Pharmaust logo

PAA - Pharmaust Share Price

A$0.096 0.0  0.0%

Last Trade - 6:46am

Sector
Healthcare
Size
Micro Cap
Market Cap £16.7m
Enterprise Value £15.5m
Revenue £1.90m
Position in Universe 1320th / 1911
Bullish
Bearish
Unlock PAA Revenue
Momentum
Relative Strength (%)
1m -3.45%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -65.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
2.42 2.75 3.33 3.30 4.36 4.12 +11.2%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, PharmAustLimited revenues decreased 27% to A$1.8M. Net lossincreased 72% to A$832K. Revenues reflect Revenue decreaseof 37% to A$1.1M, Other income decrease of 3% to A$688K.Higher net loss reflects Depreciation increase from A$73Kto A$149K (expense), Share-based payment expense increasefrom A$29K to A$81K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

PAA Revenue Unlock PAA Revenue

Net Income

PAA Net Income Unlock PAA Revenue

Normalised EPS

PAA Normalised EPS Unlock PAA Revenue

PE Ratio Range

PAA PE Ratio Range Unlock PAA Revenue

Dividend Yield Range

PAA Dividend Yield Range Unlock PAA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
PAA EPS Forecasts Unlock PAA Revenue
Profile Summary

Pharmaust Limited is a drug discovery and development company. The principal activities of the Company are to develop its own drug discovery intellectual property, namely approximately three platforms for the treatment of different types of cancers in humans and animals, as well as providing specialized medicinal and synthetic chemistry services on a contract basis to clients. The Company's segments are Corporate and Pharmaceutical. The Pharmaceutical segment provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The Corporate segment covers all the corporate overhead expenses. Its subsidiaries include Pitney Pharmaceuticals Pty Ltd, which is engaged in business of developing therapeutic cancer products, and Epichem Pty Ltd, which offers a range of rare and hard to find pharmaceutical impurities, degradants and metabolites of active ingredients and excipients, particularly for over-the-counter and generic drugs.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated August 3, 2000
Public Since October 5, 2001
No. of Shareholders: n/a
No. of Employees: 52
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 316,729,920
Free Float (0.0%)
Eligible for
ISAs
SIPPs
PAA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for PAA
Upcoming Events for PAA
Friday 5th November, 2021 Estimate
PharmAust Ltd Annual Shareholders Meeting
Frequently Asked Questions for Pharmaust
What is the Pharmaust share price?

As of 6:46am, shares in Pharmaust are trading at A$0.096, giving the company a market capitalisation of £16.7m. This share price information is delayed by 15 minutes.

How has the Pharmaust share price performed this year?

Shares in Pharmaust are currently trading at A$0.096 and the price has moved by -4% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Pharmaust price has moved by -28.15% over the past year.

What are the analyst and broker recommendations for Pharmaust?

There are no analysts currently covering Pharmaust.

When will Pharmaust next release its financial results?

Pharmaust is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Pharmaust dividend yield?

Pharmaust does not currently pay a dividend.

Does Pharmaust pay a dividend?

Pharmaust does not currently pay a dividend.

When does Pharmaust next pay dividends?

Pharmaust does not currently pay a dividend.

How do I buy Pharmaust shares?

To buy shares in Pharmaust you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Pharmaust?

Shares in Pharmaust are currently trading at A$0.096, giving the company a market capitalisation of £16.7m.

Where are Pharmaust shares listed? Where are Pharmaust shares listed?

Here are the trading details for Pharmaust:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: PAA
What kind of share is Pharmaust?

Based on an overall assessment of its quality, value and momentum, Pharmaust is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Pharmaust share price forecast 2021?

We were not able to load any forecast data for Pharmaust.

How can I tell whether the Pharmaust share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharmaust. Over the past six months, the relative strength of its shares against the market has been -19.39%. At the current price of A$0.096, shares in Pharmaust are trading at -21.64% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Pharmaust PE Ratio?

We were not able to find PE ratio data for Pharmaust.

Who are the key directors of Pharmaust?

Pharmaust's management team is headed by:

Colette Sims - OTH
Sam Wright - SEC
John Horton - OTH
Robert Bishop - EDR
Martine Keenan - CEO
Neville Bassett - NED
Who are the major shareholders of Pharmaust?

Here are the top five shareholders of Pharmaust based on the size of their shareholding:

Hybrid Holdings Pty. Ltd. Corporation
Percentage owned: 6.98% (22.1m shares)
Blommestein (Gerald James Van) Individual Investor
Percentage owned: 5.07% (16.0m shares)
Aston (Roger) Individual Investor
Percentage owned: 4.75% (15.0m shares)
Bishop (Robert Charles) Individual Investor
Percentage owned: 2.91% (9.21m shares)
Hughes (Marcus Paul) Individual Investor
Percentage owned: 1.89% (6.00m shares)
Similar to PAA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.